TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Resistance Training in Radically Treated Respiratory Cancer Patients: a Prospective Randomized Multicenter Study
Brief Summary: The first part of the study is an observational part. In eligible patients with early stage respiratory cancer, the primary and secondary endpoints will be evaluated before and after their scheduled radical cancer therapy. The measured variables, include a blood sample, pulmonary function tests, level of dyspnea, exercise tests, measurement of body composition, respiratory and peripheral muscle force, health related quality of life and psychological status. Only registered participants having completed a radical treatment and having either less than 70% of the predicted normal value of the quadriceps force (QF) or a decrease of more than 10% predicted value of the QF between pre-and post radical treatment, will be allowed to participate to the second part of the study. These patients will then be randomized in three groups. Group A, the control group, will have the usual care and follow up according to clinical symptoms. Group B will be offered a conventional resistance training program (CRT), and group C, will be offered a whole body vibration resistance training (WBV) on the FITVIBE-platform. All previous variables will be measured after 6 and 12 weeks of training.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised exercise in hospital | Intervention Type: OTHER; Name: Supervised exercise in hospital; Assigned to Arm(s): Exercise Intervention
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional resistance training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Whole body vibration resistance training | Intervention Type: OTHER; Name: Conventional resistance training; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Whole body vibration resistance training; Assigned to Arm(s): 3
C: Arm Label: Patients Pre and Post-chemotherapy; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and relaxation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and physical activity | Arm Label: 4; Type: NO_INTERVENTION; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: CBT and relaxation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CBT and physical activity; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Lnug Transplantation
Brief Summary: A prospective, interventional rehabilitation program was initiated to improve exercise capacity and psychosocial functioning in patients after lung transplantation (LTx) and to evaluate long-term effects on health-related quality of life (HRQoL).

Study subjects were randomized to either intervention or to control group and were followed with regular cardiopulmonary exercise testings and HRQoL measurements (SF-36) for 36±3 months after LTx. Patient characteristics did not differ concerning age, gender, and diagnosis at study entry. IG patients received regular psychosocial support and performed a home-based supervised ergometer training program. CG patients were recommended to perform regular exercising.


Options:
A: Arm Label: LTGO-Home Based Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: LTGO-Home Based Exercise | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: LTGO-Home Based Exercise; Assigned to Arm(s): LTGO-Home Based Exercise | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
B: Arm Label: Tele-coaching + Usual Care; Type: EXPERIMENTAL; Interventions: Behavioral: Tele-coaching + Usual Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tele-coaching + Usual Care; Assigned to Arm(s): Tele-coaching + Usual Care
C: Arm Label: High-Intensity Training; Type: EXPERIMENTAL; Interventions: Behavioral: High-intensity training | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: High-intensity training; Assigned to Arm(s): High-Intensity Training
D: Intervention Type: BEHAVIORAL; Name: exercise training; psychosocial support; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Nurse-driven ICT-supported Disease Management Program to Improve the Treatment of Patients With Atrial Fibrillation.
Brief Summary: * Randomized controlled trial comparing specialized AF Clinic with 'care as usual'
* Hypothesis: treatment of AF patients in the AF-Clinic by a nurse, specialised in AF, using guideline-based dedicated software, under supervision of a cardiologist, is efficient, safe and not inferior to care as usual by a cardiologists.


Options:
A: Arm Label: AF Clinic; Type: EXPERIMENTAL; Interventions: Other: AF Clinic | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Care as Usual | Intervention Type: OTHER; Name: AF Clinic; Assigned to Arm(s): AF Clinic | Intervention Type: OTHER; Name: Care as Usual; Assigned to Arm(s): Care as Usual
B: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
C: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Weekly patient self-testing of prothrombin time | Arm Label: Arm 2; Type: OTHER; Interventions: Other: High quality anticoagulation management (HQACM) with conventional monthly testing | Intervention Type: PROCEDURE; Name: Weekly patient self-testing of prothrombin time; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: High quality anticoagulation management (HQACM) with conventional monthly testing; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Nurse-driven ICT-supported Disease Management Program to Improve the Treatment of Patients With Atrial Fibrillation.
Brief Summary: * Randomized controlled trial comparing specialized AF Clinic with 'care as usual'
* Hypothesis: treatment of AF patients in the AF-Clinic by a nurse, specialised in AF, using guideline-based dedicated software, under supervision of a cardiologist, is efficient, safe and not inferior to care as usual by a cardiologists.


Options:
A: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban
B: Arm Label: AF Clinic; Type: EXPERIMENTAL; Interventions: Other: AF Clinic | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Care as Usual | Intervention Type: OTHER; Name: AF Clinic; Assigned to Arm(s): AF Clinic | Intervention Type: OTHER; Name: Care as Usual; Assigned to Arm(s): Care as Usual
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Medication Education Tool | Intervention Type: OTHER; Name: Medication Education Tool; Assigned to Arm(s): 2
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Denervation in Patients With Refractory Hypertension
Brief Summary: The purpose of this study is to investigate the clinical utility of renal denervation for the treatment of refractory hypertension.


Options:
A: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: Renal sympathetic denervation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Renal sympathetic denervation; Assigned to Arm(s): Renal sympathetic denervation
B: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Device: MDT-2211 Renal Denervation System | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MDT-2211 Renal Denervation System; Assigned to Arm(s): Renal denervation
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
D: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation | Intervention Type: DEVICE; Name: Renal Denervation; Assigned to Arm(s): Renal Denervation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Denervation in Patients With Refractory Hypertension
Brief Summary: The purpose of this study is to investigate the clinical utility of renal denervation for the treatment of refractory hypertension.


Options:
A: Arm Label: Renal Denervation Treatment; Type: N/A; Interventions: Device: Medtronic Renal Denervation System | Intervention Type: DEVICE; Name: Medtronic Renal Denervation System; Assigned to Arm(s): Renal Denervation Treatment
B: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation | Intervention Type: DEVICE; Name: Renal Denervation; Assigned to Arm(s): Renal Denervation
C: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Device: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA) | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Other: Sham procedure | Intervention Type: DEVICE; Name: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA); Assigned to Arm(s): Renal sympathetic denervation | Intervention Type: OTHER; Name: Sham procedure; Assigned to Arm(s): Sham procedure
D: Arm Label: Circumferential PVI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: Circumferential PVI+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PVI+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): Circumferential PVI | Intervention Type: PROCEDURE; Name: Circumferential PVI+renal denervation; Assigned to Arm(s): Circumferential PVI+renal denervation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Placebo Controlled Study On The Neuroprotective And Anti-Atherogenic Effects Of Palm TocotrienolRich Fraction(Palm Vitamin E)
Brief Summary: The purpose of the study is to assess the neuroprotective, anti atherogenic and hepatoprotective properties of tocotrienols (palm vitamin E) supplementation as determined by white matter lesion load on serial magnetic resonance imaging (MRI), carotid artery magnetic resonance angiography (MRA) and liver ultrasound (US) as well as lipid profile analysis.


Options:
A: Arm Label: Lepicol probiotic & prebiotic formula+simple lifestyle advice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepicol probiotic & prebiotic formula, Other: Simple lifestyle advice | Arm Label: Simple lifestyle advice alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Simple lifestyle advice | Intervention Type: DRUG; Name: Lepicol probiotic & prebiotic formula; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice | Intervention Type: OTHER; Name: Simple lifestyle advice; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice, Simple lifestyle advice alone
B: Arm Label: Prebiotic Fibre; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotic fibre, Behavioral: Weight Loss | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Behavioral: Weight Loss | Arm Label: Weight Loss; Type: OTHER; Interventions: Behavioral: Weight Loss | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotic fibre; Assigned to Arm(s): Prebiotic Fibre | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Weight Loss; Assigned to Arm(s): Placebo, Prebiotic Fibre, Weight Loss
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Omega-3 carboxylic acids 4g / day; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 carboxylic acids | Arm Label: Dapagliflozin, 10mg / day; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin | Arm Label: Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 carboxylic acids, Drug: Dapagliflozin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Omega-3 carboxylic acids; Assigned to Arm(s): Omega-3 carboxylic acids 4g / day, Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin, 10mg / day, Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: MRI(+ve),; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Arm Label: MRI(-ve); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 200mg of Palm vitamin E (tocotrienols) or placebo; Assigned to Arm(s): MRI(+ve),, MRI(-ve)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Placebo Controlled Study On The Neuroprotective And Anti-Atherogenic Effects Of Palm TocotrienolRich Fraction(Palm Vitamin E)
Brief Summary: The purpose of the study is to assess the neuroprotective, anti atherogenic and hepatoprotective properties of tocotrienols (palm vitamin E) supplementation as determined by white matter lesion load on serial magnetic resonance imaging (MRI), carotid artery magnetic resonance angiography (MRA) and liver ultrasound (US) as well as lipid profile analysis.


Options:
A: Arm Label: 25 mg INT-747; Type: ACTIVE_COMPARATOR; Interventions: Drug: INT-747 | Arm Label: 50 mg INT-747; Type: ACTIVE_COMPARATOR; Interventions: Drug: INT-747 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: INT-747; Assigned to Arm(s): 25 mg INT-747, 50 mg INT-747 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
C: Arm Label: Metformin, Adiponectine, Arterial Compliance; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin, Adiponectine, Arterial Compliance
D: Arm Label: MRI(+ve),; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Arm Label: MRI(-ve); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 200mg of Palm vitamin E (tocotrienols) or placebo; Assigned to Arm(s): MRI(+ve),, MRI(-ve)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Placebo Controlled Study On The Neuroprotective And Anti-Atherogenic Effects Of Palm TocotrienolRich Fraction(Palm Vitamin E)
Brief Summary: The purpose of the study is to assess the neuroprotective, anti atherogenic and hepatoprotective properties of tocotrienols (palm vitamin E) supplementation as determined by white matter lesion load on serial magnetic resonance imaging (MRI), carotid artery magnetic resonance angiography (MRA) and liver ultrasound (US) as well as lipid profile analysis.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Study Arm A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm B | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm C | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm D | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm B; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm C; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm D; Assigned to Arm(s): 4
B: Arm Label: PGZ; Type: EXPERIMENTAL; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): PGZ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MRI(+ve),; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Arm Label: MRI(-ve); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 200mg of Palm vitamin E (tocotrienols) or placebo; Assigned to Arm(s): MRI(+ve),, MRI(-ve)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Drug: Placebo wafers | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q, Drug: Placebo capsules | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules, Drug: Placebo wafers | Intervention Type: DRUG; Name: Vitamin E, Vitamin C, and Alpha-lipoic Acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coenzyme Q; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo wafers; Assigned to Arm(s): 1, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Brief Summary: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy


Options:
A: Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD0530, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: AZD0530; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2, Active Comparator | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2, Active Comparator
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1
C: Arm Label: Treatment (temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: temsirolimus | Intervention Type: DRUG; Name: temsirolimus; Assigned to Arm(s): Treatment (temsirolimus)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2

Answer: D